TRL is self-reported. Here is how to prove it credibly

 Many TRL assessments are self-reported. That is not necessarily wrong, but it creates a trust problem: two teams can claim the same TRL while one has real proof and the other has a slide deck.

The fix is simple: stop treating TRL as a label. Treat TRL as a set of claims that must be supported by evidence artifacts.

A credible TRL story usually includes three elements:

1. Tested objective: what exactly was tested (algorithm, workflow, data pipeline, user task, outcome mechanism).
   
   
2. Test context: where and with whom it was tested (synthetic data, retrospective dataset, simulated workflow, clinical setting).
   
   
3. Decision unlocked: what decision the proof enables next (pilot expansion, funding readiness, partner commitment, procurement step).
   
   

If your TRL statement does not contain these three elements, it sounds like marketing. If it contains them, it reads like engineering and science. That difference is everything in healthcare.

A practical way to operationalize this is to build a “TRL evidence table” with one row per TRL step: proof goal, method, dataset or setting, success criteria, and evidence artifact (report, analysis, protocol, results summary). This gives you a repeatable structure that also fits EU funding workplans.

This is where real-world data can be powerful. Retrospective analysis can validate feasibility and performance signals faster than prospective studies, especially in early–mid stages. It does not replace later operational evidence, but it can dramatically increase credibility early on.

Worthmed® typically supports teams by converting TRL into a documented evidence pathway, often combining a structured evidence review with real-world data analysis to make the maturity claim defensible.

‍